Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma

1. Bai, Y, Orfao, A, Chim, CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol 2018; 181: 11–26.
Google Scholar | Crossref | Medline2. Kumar, S, Paiva, B, Anderson, KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346.
Google Scholar | Crossref | Medline3. Yao, Q, Bai, Y, Orfao, A, et al. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol 2019; 9: 449.
Google Scholar | Crossref | Medline4. Yao, Q, Bai, Y, Orfao, A, et al. Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. J Mol Diagn 2020; 22: 679–684.
Google Scholar | Crossref | Medline5. Zamagni, E, Nanni, C, Mancuso, K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 2015; 21: 4384–4390.
Google Scholar | Crossref | Medline6. Bartel, TB, Haessler, J, Brown, TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068–2076.
Google Scholar | Crossref | Medline7. Sachpekidis, C, Goldschmidt, H, Dimitrakopoulou-Strauss, A. Positron Emission Tomography (PET) radiopharmaceuticals in multiple myeloma. Molecules 2019; 25: 134.
Google Scholar | Crossref8. Fontana, F, Ge, X, Su, X, et al. Evaluating acetate metabolism for imaging and targeting in multiple myeloma. Clin Cancer Res 2017; 23: 416–429.
Google Scholar | Crossref | Medline9. Ho, C-l, Chen, S, Leung, YL, et al. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. J Nucl Med 2014; 55: 749–752.
Google Scholar | Crossref | Medline10. Moreau, P, Attal, M, Hulin, C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019; 394: 29–38.
Google Scholar | Crossref | Medline11. Voorhees, PM, Kaufman, JL, Laubach, JP, et al. Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood 2020; 136: 936–945.
Google Scholar | Crossref | Medline12. Clemens, PL, Yan, X, Lokhorst, HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokine 2017; 56: 915–924.
Google Scholar | Crossref13. Maloney, DG . Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366: 2008–2016.
Google Scholar | Crossref | Medline | ISI14. Chim, CS, Wong, VKC, Au, YLE, et al. PS1432 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious, hence financially affordable with enormous economic impact for relapsed/refractory multiple myeloma in less affluent countries. HemaSphere 2019; 3: 659–660.
Google Scholar | Crossref15. Chim, J, Wong, V, AU, E, et al. 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma. J Clin Oncol 2019; 37: e19521–e19521.
Google Scholar | Crossref16. Chim, CS, Kumar, SK, Orlowski, RZ, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 2018; 32: 252–262.
Google Scholar | Crossref | Medline17. Facon, T, Kumar, S, Plesner, T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380: 2104–2115.
Google Scholar | Crossref | Medline18. Usmani, SZ, Rodriguez-Otero, P, Bhutani, M, et al. Defining and treating high-risk multiple myeloma. Leukemia 2015; 29: 2119–2125.
Google Scholar | Crossref | Medline19. Baysal, M, Demirci, U, Umit, E, et al. Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. Sci Rep 2020; 10: 5991.
Google Scholar | Crossref | Medline20. Martinez-Lopez, J, Blade, J, Mateos, M-V, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118: 529–534.
Google Scholar | Crossref | Medline21. Perrot, A, Lauwers-Cances, V, Corre, J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 2018; 132: 2456–2464.
Google Scholar | Crossref | Medline22. Martinez-Lopez, J, Lahuerta, JJ, Pepin, F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073–3079.
Google Scholar | Crossref | Medline | ISI23. Mateos, M-V, Dimopoulos, MA, Cavo, M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018; 378: 518–528.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif